TiumBio KRX:321550KOSDAQ
티움바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days5
DART filings, 7 days6
Articles tracked5since Sep 11
In Q2 2026, TiumBio reported revenue of ₩4.5bn, up 71.3% year on year, and an operating loss of ₩4.2bn. TiumBio (티움바이오) appeared in 5 Korean news articles and 6 DART filings over the past seven days. Coverage peaked on Sep 30 with 5 articles. It was most often mentioned alongside SK Discovery.
Filing signals M&A / stake deal 4 quarters of losses Screener
TiumBio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.5bn | +71.3% | −₩4.2bn margin −94.8% | −₩4.5bn |
| Q1 2026 | ₩3.0bn | +40.1% | −₩4.5bn margin −153.8% | −₩5.8bn |
| Q4 2025 derived | ₩4.4bn | – | −₩2.8bn margin −62.6% | −₩2.3bn |
| Q3 2025 | ₩3.1bn | – | −₩4.5bn margin −144.8% | −₩5.8bn |
| Q2 2025 | ₩2.6bn | +19.5% | −₩3.5bn margin −133.7% | −₩2.3bn |
| Q1 2025 | ₩2.1bn | +5.8% | −₩5.3bn margin −253.8% | −₩8.4bn |
| Q4 2024 derived | – | – | −₩5.2bn | ₩3.0bn |
| Q3 2024 | – | – | −₩4.4bn | −₩4.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
TiumBio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest TiumBio news Korean headlines
-
티움바이오, SK플라즈마 지분 93억원에 처분…자기자본 대비 21.47%
2 more on this story · 1 outlets
- 티움바이오, SK플라즈마 지분 93억원에 처분…자기자본 대비 21.47%이데일리 · Sep 30 16:23
- 티움바이오, SK플라즈마 지분 93억원에 처분…자기자본 대비 21.47%이데일리 · Sep 30 16:25